数据链接：
官方服务：
资源简介：
Lapatinib-treated HER2+/ER- tumorsa.
应用场景：
创建时间：
2021-05-05
相关数据集
Supplemental Materials2 (Sphere-formation assay)
TCCSUP-Control/-Knockdown/-Knockout cells were incubated with DMEM/F12 supplemented with B27, N2, epidermal growth factor and basic fibroblast growth factor in the presence of ethanol (mock), 100 nmol
Figshare2019-10-23 更新60
RNA-seq of MMTV-Neu AXL KO tumors
AXL is activated by its ligand GAS6 and is expressed in triple-negative breast cancer cells. We report that AXL is also detected in HER2+ breast cancer specimens where its expression correlates with p
NIAID Data Ecosystem30
Age characteristics of study patients with HER2-positive BC.
Age characteristics of study patients with HER2-positive BC.
Figshare2018-10-01 更新20
BRD8 is a therapeutic vulnerability for overcoming resistance to dual ER/HER2 blockade therapy in HR+/HER2+ breast cancer
.rda file for Seurat object of scRNA-seq data from BT474 breast cancer cell lines treated with DMSO, Neratinib, Fulvestrant, and a combination of Neratinib and Fulvestrant.
Zenodo2023-05-04 更新30
Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance . Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance
HER2 plays a critical role in tumorigenesis and is associated with poor prognosis of patients with HER2-positive breast cancers. Although anti-HER2 drugs are beneficial benefits for treating breast ca
NIAID Data Ecosystem30
